Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–78
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All participants (with mild, moderate or severe renal impairment, end stage renal disease, or healthy):
a female must be non-pregnant, non-breast feeding and if she is of reproductive potential: must agree to use (and/or have their partner use) two acceptable methods of birth control beginning at screening, throughout the study and until 2 weeks after the last dosing of study drug
a female of non-childbearing potential: must have undergone a sterilization procedure at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at least 1 year prior to the first dose
a non-vasectomized male participant must agree to use a condom with spermicide or abstain from sexual intercourse from the first dose until 90 days after the last dose of study drug
a male participant must agree not to donate sperm from dosing until 90 days after the last dose of study drug
has a body mass index (BMI) ≤ 40.0 kg/m\^2
is a non-smoker or moderate smoker (≤ 20 cigarettes/day or the equivalent)
Participants with mild, moderate or severe renal impairment or end stage renal disease:
has a clinical diagnosis of renal impairment and meets the protocol-specified renal impairment function qualifications at the prestudy visit (screening)
Healthy participants:
has baseline creatinine clearance ≥ 90 mL/min based on Cockcroft-Gault equation
is judged to be in good health based on medical history, physical examination, vital signs, pulse oximetry, and laboratory safety tests
You may not be if
All participants (with mild, moderate or severe renal impairment, end stage renal disease, or healthy):
is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
history or presence of clinically significant medical or psychiatric condition or disease
history of stroke, chronic seizures, or major neurological disorders
history of malignant neoplastic disease
history or presence of alcoholism or drug abuse within the past 6 months
female participant who is pregnant or lactating
Participants with mild, moderate or severe renal impairment:
has had a renal transplant or has had nephrectomy
has uncontrolled type 2 diabetes mellitus (T2DM), a history of Type 1 diabetes, or ketoacidosis
history of significant endocrine, gastrointestinal, cardiovascular, hematological, immunological, respiratory, or genitourinary diseases
Participants with end stage renal disease (ESRD):
had a failed renal allograft within the last 2 years prior to the first dose, or a successful renal allograft
has uncontrolled T2DM, a history of Type 1 diabetes, or ketoacidosis
history of significant endocrine, gastrointestinal, cardiovascular, hematological, immunological, respiratory, or genitourinary diseases
Healthy participants:
history of hypoglycemia, glucose intolerance, T2DM, or ketoacidosis
history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
Clareo Health | Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
